Phase 1b/2 study evaluating telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with budigalimab in patients (pts) with advanced non-squamous (NSQ) non-small cell lung cancer (NSCLC) with no prior treatment for advanced disease and no actionable genomic alterations.

Authors: David Ross Camidge, Nicolas Girard, Shun Lu, Shirish M. Gadgeel, Kristof Cuppens, Se-Hoon Lee, Hidehito Horinouchi, Tae Min Kim, Angelo Delmonte, Elvire Pons-Tostivint, Robert M. Jotte, Nivedita Aanur, Han Coburn, Qi Jiang, Theodore S. Jennaro, Tony Navas, Yan Li, Jonathan W. Goldman

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps8655

Source: Full article

---

Abstract

TPS8655